Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR139 | Q6DWJ6 | 19/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | ATM | Q13315 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30518967 | 1.00 | GPR139 (1.00) | GPR139MEN1KMT2AATM | |
| SCHEMBL12443252 | 0.85 | GPR139 (0.74) | GPR139MEN1KMT2AATM | |
| SCHEMBL2010690 | 0.84 | SLC6A9 (0.83) | GPR139MEN1KMT2AATM | |
| SCHEMBL23975012 | 0.83 | GPR139 (1.00) | GPR139MEN1KMT2AATM | |
| SCHEMBL10340670 | 0.81 | GPR139 (0.78) | GPR139MEN1KMT2AATM | |
| SCHEMBL4801790 | 0.77 | PSMB5 (0.70) | GPR139MEN1KMT2AATM | |
| SCHEMBL10004955 | 0.77 | KMT2A (0.62) | GPR139MEN1KMT2AATM | |
| SCHEMBL8858800 | 0.77 | KMT2A (0.61) | GPR139MEN1KMT2AATM | |
| SCHEMBL17847355 | 0.77 | KMT2A (0.78) | GPR139MEN1KMT2AATM | |
| SCHEMBL2984329 | 0.76 | KMT2A (0.60) | GPR139MEN1KMT2AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023165262-A1 | THIENO-NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海科技大学 | 2023-09-07 | — | — | WO | disclosed |
| WO-2023165263-A1 | PYRROLOTRIAZINONE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海科技大学 | 2023-09-07 | — | — | WO | disclosed |
| US-20210338680-A1 | METHODS RELATED TO OPIOID THERAPEUTICS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210338680-A1 | METHODS RELATED TO OPIOID THERAPEUTICS | OPRL1, OPRK1, GPR139 | GPR139 3/4885MEN1 4873/4885KMT2A 1691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.